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Hihlights 
 Skin reactions and fever were the most common IARs attributed to alemtuzumab 
infusions. 
 Modified premedication scheme may reduce overall IARs associated with alemtuzumab. 
 Intravenous compared to oral administration of antipyretics significantly reduces the 
occurrence of fever.  
Abstract 
 
Objective: Infusion-associated reactions (IARs) occur in >90% patients with multiple 
sclerosis (MS) treated with alemtuzumab. We aimed to study the frequency of IARs at 2 sites 
using 5 days of steroids (1g/day of IV methylprednisolone), but otherwise distinct protocols.  
Methods: This was retrospective chart review of 38 consecutive MS patients who were 
treated with alemtuzumab from June 2015 till February 2017 at Department of Neurology, 
University Hospital Center Zagreb, Croatia and Department of Neurology, University 
Medical Centre Ljubljana, Slovenia. 
Results: Seventeen patients (44.7%) did not experience IARs. Skin reactions and fever were 
the most common IARs attributed to alemtuzumab infusions and they were most frequent on 
Day 5 and Day 1, respectively. We have observed significant differences in the occurrence of 
fever (p=0.005) depending on the site of alemtuzumab administration which could be 
explained by different antipyretics used; fever was absent in the Slovenian cohort because 
high dose intravenous metamizole was administered. Two out of 9 treatment naïve, and 19 out 
of 29 patients who previously received immunomodulatory treatment had IARs (χ2=5.208, 
p=0.022). 
Conclusion: Modified premedication scheme consisting of 1g/day of IV methylprednisolone 
throughout all 5 days of alemtuzumab treatment may reduce overall IARs. Intravenous 
administration of antipyretics may work better than oral administration. 
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 Introduction 
Infusion-associated reactions (IARs) occur in >90% patients with multiple sclerosis (MS) 
treated with alemtuzumab, despite all patients receive premedication consisting of 1 g/day IV 
methylprednisolone immediately before alemtuzumab administration on the first 3 out of 5 
days of treatment. (1,2) Furthermore, most physicians use concomitant treatment with 
antipyretic and antihistamine. 
The aim of this study was to study the frequency of IARs at 2 sites using 5 days of steroids 
(1g/day of IV methylprednisolone), but otherwise distinct protocols. 
 
Methods 
This was retrospective chart review of consecutive patients with relapsing remitting MS who 
were treated with alemtuzumab from June 2015 till February 2017 at Department of 
Neurology, University Hospital Center Zagreb, Zagreb, Croatia and Department of 
Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia. All patients received 
alemtuzumab in outpatient clinic and all adverse events (AE) were recorded on the paper 
chart and entered in the electronic hospital records. Temperature, blood pressure and heart 
rate were measured every hour during the infusion, with additional measurements taken if the 
patient reported new symptoms. Other IARs were spontaneously reported/observed during the 
infusion visit. AE occurring after the infusion were reported by the patient the next morning 
and entered in the patient’s chart. 
IAR were defined as any adverse event beginning during or within 24 hours after an 
alemtuzumab infusion. Adverse events associated with steroid use (flushing, insomnia, taste 
changes, elevated blood pressure) were not considered as IARs.  
The Croatian cohort received alemtuzumab in an outpatient neurological department, and 
Slovenian cohort received alemtuzumab in an inpatient neurological department. 
Along with his, the need for admitting the patient in the inpatient service was recorded for the 
Croatian cohort. 
Premedication consisted of IV methylprednisolone 1 g / 5 days in all patients. There was a 
difference in other concomitant treatments, the Croatian cohort received PO acetaminophen 1 
g / 5 days and IM chloropyramine 20 mg / 5 days, while the Slovenian cohort received i.v. 
metamizole 2.5 g / 5 days and i.v. clemastine 2 mg / 5 days. The duration of steroid infusion 
was 60 min. Other medications were given immediately after steroid infusion and 
alemtuzumab infusion started 5 min after. 
Differences in the distribution of qualitative variables were determined with the χ2 test, while 
the differences in quantitative variables were determined with t-test and Mann-Whitney test. P 
values less than 0.05 were considered as significant. Software used for statistical analysis was 
IBM SPSS, version 20. 
 
Results 
Altogether 38 RRMS patients (20 from Croatia and 18 from Slovenia) were enrolled. Baseline 
patients’ characteristics are presented in Table 1. Alemtuzumab was a 1st therapy in 9 
(23.7%), second in 18 (47.4%), 3
rd
 in 9 (23.7%) and 4
th
 in 1 (2.6%) and 5
th
 in 1 (2.6%) 
patient. Most patients received interferons 20 (52.6%), followed by glatiramer acetate 7 
(18.4%), dimethyl fumarate 5 (13.2%), natalizumab 6 (15.8%) and fingolimod 4 (10.5%). For 
patients switched from interferons, glatiramer acetate and dimethyl fumarate no specific 
washout period was used. For patients who were switched from fingolimod, the washout 
period was 6 weeks or until lymphocytes count returned to normal and for natalizumab the 
wash out period was 12 weeks. 
Total number of IARs, timing and frequency of IARs in the two cohorts is provided in Table 
2. Skin reactions and fever were the most common IARs attributed to alemtuzumab infusions 
and they were most frequent on Day 5 and Day 1, respectively (Figure 1). There was a 
significant difference between groups in the frequency of fever (Table 2). 
In the Croatian cohort, in 3 patients IARs resulted in hospitalization, in all 3 cases due to 
worsening of preexisting neurological deficits associated with fever (in one patient 
paraparesis and in 2 patients cognitive dysfunction). In the Slovenian cohort in one patient the 
5 cycle was administered with a 3 days delay due to rash.  
Two out of 9 treatments naïve, and 19 out of 29 patients who previously received 
immunomodulatory treatment had IARs (χ2=5.208, p=0.022). 
 
Discussion 
 
With the modification od the premedication given in which we extended methylprednisolone 
through days 4 and 5, 17 patients (44.7%) did not experience IARs. As well, we have 
observed a biphasic occurrence of IARs, fever being the most common on the 1
st
 day, and 
rash being the most common on the 5
th
 day of therapy.  
Prevention of alemtuzumab associated IARs is of great importance, as some of IARs 
(especially fever and skin reactions) may lead to treatment discontinuation. In the CARE-MS 
I and II studies, in 45 patients, the first treatment course was suspended/interrupted, and of 
these, only 24 patients went on to eventually complete their first and second treatment 
courses. (3)  
The most frequently observed IARs in our cohort were skin reactions, occurring in 13 
(34.2%) patients, exclusively on days 3 through 5, and peaking on day 5, which is different 
comparing to 66.1% of patients with skin reactions in the CARE-MS I and II studies (Table 
3). (3) This difference could be explained either with higher doses of methylprednisolone or 
different antihistamines used (the most frequent antihistamines used in CARE-MS I and II 
studies were diphenhydramine, cetirizine, fexofenadine, hydroxyzine, and loratadine, while 
we used chloropyramine and clemastine). (3) Similar findings were observed in a recently 
published study in which authors used methylprednisolone through days 1 to 3 only, and 
desloratadine and ranitidine as antihistamines, where skin reactions were noticed in 5/15 
(33.3%) patients on days 4 and 5. (4) In our cohort, skin reactions resulted in 3 days treatment 
interruption in only one case. 
The second most common IAR was fever, occurring in 7 (18,4%) patients, which is 
comparable to CARE-MS I and II studies where fever occurred in 23.9% patients. (3) Fever 
was associated with worsening of previous neurological symptoms in 3 cases, which resulted 
in admission of patients in the inpatient neurological service. This phenomenon of recurrence 
of previous MS relapse symptoms, typically lasting a few hours, was previously reported in 
association with alemtuzumab infusions. (5) Recently, it has been shown that C-reactive 
protein and procalcitonin peak at serum levels consistent with septic conditions during the 
first five days of alemtuzumab treatment, which is very important to know in the context of 
high fever as an IAR. (4) Furthermore, we have observed significant differences between two 
cohorts in the occurrence of fever. This could be explained by different antipyretics used; 
fever was absent in the Slovenian cohort where high dosed of intravenous metamizole was 
administered.  
Finally, we have found association between IARs and previous disease modifying treatment. 
This finding is interesting because recently it has been emphasized how the immediate and 
long-term consequences of sequential drug use and the optimum order in which they should 
be used in MS is unclear but may significantly affect efficacy, adverse events, and longer-
term immunocompetence. (6) Although this observation is not supported by the results of the 
CARE-MS I and II studies, there is a significant difference in previous MS medications 
between two cohorts which can in part explain this. In the CARE-MS II trial, only 15 patients 
(4%) received natalizumab, and none received fingolimod or dimethyl fumarate. (2) Finally, it 
has to be noted that this observation may be related to the infusion site, significantly more of 
the patients in Croatian cohort had had previous disease modifying treatments. 
This study has several limitations, first of all retrospective data collection and relatively small 
number of patients. However, there is clear lack of postmarketing studies on IARs 
management in patients with MS receiving alemtuzumab.  
In conclusion, modified premedication scheme consisting of 1g/day of IV methylprednisolone 
throughout all 5 days of alemtuzumab treatment may reduce overall IARs. Intravenous 
administration of antipyretics may work better than oral administration. 
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Tables 
 
Table 1. Baseline patients’ characteristics. 
 HR cohort (N=20) SLO cohort N 
(N=18) 
p value 
Gender (F/M) 12/8 15/3 0.113 
Age (years) 30.5±8.57 31.67±8.21 0.672 
First line/other lines 2/18 7/11 0.036* 
Disease duration 4.8±2.7 4.6±7.0 0.870 
EDSS 3.0 (2.0-6.0) 3.0 (0-6.0) 0.575 
Number of relapses 
in the previous year 
1.5 (1-3)  1 (1-3) 0.280 
*statistically significant 
 
Table 2. Total number of IARs, timing and frequency of IARs in the two cohorts 
 HR cohort (N=20) SLO cohort (N=18) p value 
Overall AEs 
Any AE 14 (70.0%) 7 (38.9%) 0.054 
Day 1 10 (50.0%) 2 (11.1%) 0.010* 
Day 2 2 (10.0%) 1 (5.6%) 0.612 
Day 3 4 (20.0%) 4 (22.2%) 0.867 
Day 4 6 (30.0%) 4 (22.2%) 0.586 
Day 5 9 (45.0%) 4 (22.2%) 0.139 
Specific AEs 
Fever 7 (35.0%) 0 0.005* 
Skin reactions 8 (40.0%) 5 (27.8%) 0.428 
Bradycardia 2 (10.0%) 0 0.168 
Headache 1 (5.0%) 1 (5.6%) 0.938 
Pain 1 (5.0%) 1 (5.6%) 0.938 
Fatigue 0 1 (5.6%) 0.285 
*statistically significant 
 
Table 3. Comparison in IARs between pooled results of the Croatian and Slovenian cohorts 
and pooled CARE MS results (3). 
 Pooled results of the Croatian and 
Slovenian cohorts (N=38) 
Pooled CARE MS results (N=811)  
Fever 7 (18.4%) 194 (23.9%) 
Skin reactions 13 (34.2%) 536 (66.1%) 
Bradycardia 2 (5.3%) Not reported 
Headache 2 (5.3%) 348 (42.9%) 
Pain 2 (5.3%) 39 (4.8%) 
Fatigue 1 (2.6%) 64 (7.9%) 
 
  
Figures 
 
Figure 1. Distribution of fever and skin reactions. 
HR – Croatian cohort; SLO – Slovenian cohort. 
 
 
 
